Chloroquine

• 

  Subject Areas on Research

  • 1,2,4-Trioxanes as potential antimalarial agents. 
  • A cross-sectional survey of Plasmodium falciparum pfcrt mutant haplotypes in the Democratic Republic of Congo. 
  • A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria. 
  • A molecular marker for chloroquine-resistant falciparum malaria. 
  • ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. 
  • Agonist-induced internalization of the substance P (NK1) receptor expressed in epithelial cells. 
  • Amodiaquine and sulfadoxine-pyrimethamine as treatment for chloroquine-resistant Plasmodium falciparum in Rwanda. 
  • Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. 
  • Ataxia telangiectasia-mutated and p53 are potential mediators of chloroquine-induced resistance to mammary carcinogenesis. 
  • Autophagy-dependent metabolic reprogramming sensitizes TSC2-deficient cells to the antimetabolite 6-aminonicotinamide. 
  • CR1-receptor recycling in phorbol ester-activated polymorphonuclear leucocytes. 
  • Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. 
  • Chloroquine improves survival and hematopoietic recovery after lethal low-dose-rate radiation. 
  • Chloroquine resistance of Plasmodium falciparum is associated with severity of disease in Nigerian children. 
  • Chloroquine treatment of uncomplicated Plasmodium falciparum malaria in Mali: parasitologic resistance versus therapeutic efficacy. 
  • Chloroquine, quinine and quinidine inhibit calcium release from macrophage intracellular stores by blocking inositol 1,4,5-trisphosphate binding to its receptor. 
  • Chloroquine-azithromycin combination antimalarial treatment decreases risk of respiratory- and gastrointestinal-tract infections in Malawian children. 
  • Chloroquine-resistant malaria. 
  • Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. 
  • Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. 
  • Conservation of a novel vacuolar transporter in Plasmodium species and its central role in chloroquine resistance of P. falciparum. 
  • Detection of Plasmodium falciparum in pregnancy by laser desorption mass spectrometry. 
  • Discovery of novel targets of quinoline drugs in the human purine binding proteome. 
  • Disruption of lysosome function promotes tumor growth and metastasis in Drosophila. 
  • Efficacy of chloroquine on Plasmodium falciparum transmitted at Amani, eastern Usambara Mountains, north-east Tanzania: an area where malaria has recently become endemic. 
  • Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'-deoxycoformycin, deoxyadenosine and an immunotoxin. 
  • Ex Vivo Drug Susceptibility Testing and Molecular Profiling of Clinical Plasmodium falciparum Isolates from Cambodia from 2008 to 2013 Suggest Emerging Piperaquine Resistance. 
  • Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. 
  • Immunomodulator effect of picroliv and its potential in treatment against resistant Plasmodium yoelii (MDR) infection in mice. 
  • In vitro gene delivery using polyamidoamine dendrimers with a trimesyl core. 
  • In vivo and in vitro susceptibility to chloroquine of Plasmodium falciparum in Kinshasa and Mbuji-Mayi, Zaire. 
  • Influence of genotype, dose and sex on pruritogen-induced scratching behavior in the mouse. 
  • Intracellular trafficking of angiotensin II and its AT1 and AT2 receptors: evidence for selective sorting of receptor and ligand. 
  • Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines. 
  • Kinetics of poliovirus uncoating in HeLa cells in a nonacidic environment. 
  • Low temperature reversibly inhibits transport from tubular endosomes to a perinuclear, acidic compartment in African trypanosomes. 
  • Malaria researchers say global fund is buying "useless drug". 
  • Malaria: a rising incidence in the United States. 
  • Molecular approaches to the spreading problem of drug resistant malaria. 
  • Molecular diagnosis of resistance to antimalarial drugs during epidemics and in war zones. 
  • Monitoring antimalarial drug resistance: making the most of the tools at hand. 
  • Optimizing Intradermal Administration of Cryopreserved Plasmodium falciparum Sporozoites in Controlled Human Malaria Infection. 
  • Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. 
  • Parasites and progress: ethical decision-making and the Santee-Cooper Malaria study, 1944-1949. 
  • Parasitologic and clinical efficacy of 25 and 50 mg/kg of chloroquine for treatment of Plasmodium falciparum malaria in Rwandan children. 
  • Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects. 
  • Pharmacologic advances in the global control and treatment of malaria: combination therapy and resistance. 
  • Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. 
  • Prevalence and patterns of antifolate and chloroquine drug resistance markers in Plasmodium vivax across Pakistan. 
  • Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? 
  • Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. 
  • Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users. 
  • Regulation of insulin receptors in frog erythrocytes by insulin and concanavalin A. Evidence for discrete classes of insulin binding sites. 
  • Retinal nerve fibre layer thickness measurements in patients using chloroquine. 
  • Return of chloroquine antimalarial efficacy in Malawi. 
  • Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites. 
  • Return of widespread chloroquine-sensitive Plasmodium falciparum to Malawi. 
  • Synthesis and preliminary evaluation of n.c.a. iodoquine: a novel radiotracer with high uptake in cells with high ALDH1 expression. 
  • TNF-α/TNFR1 Signaling is Required for the Full Expression of Acute and Chronic Itch in Mice via Peripheral and Central Mechanisms. 
  • TSCQ study: a randomized, controlled, open-label trial of daily trimethoprim-sulfamethoxazole or weekly chloroquine among adults on antiretroviral therapy in Malawi: study protocol for a randomized controlled trial. 
  • Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. 
  • The changing landscape of Plasmodium falciparum drug resistance in the Democratic Republic of Congo. 
  • The effects of chloroquine on chick skeletal muscle in vitro. 
  • The evolution of drug-resistant malaria. 
  • The next opportunity in anti-malaria drug discovery: the liver stage. 
  • Treatment of erythrocytes with the 2-cys peroxiredoxin inhibitor, Conoidin A, prevents the growth of Plasmodium falciparum and enhances parasite sensitivity to chloroquine. 
  • Use of antimalarial drugs in Mali: policy versus reality. 
  • Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies. 
• 

  Keywords of People

  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Reiman Jr., Robert Ellis, Associate Professor of Radiology, Radiology